Agnes Klein
About Agnes Klein
Agnes Klein serves as the Director of Evaluation at Health Canada, where she has worked since 2003. She specializes in surrogate markers and pharmacogenomics, and has a background in biomedical ethics.
Work at Government of Canada
Agnes Klein has been employed at the Government of Canada since 2003, currently serving as the Director of Evaluation. In this role, she oversees evaluation processes that inform policy and program decisions. Additionally, she has held the position of Director at the Centre for Evaluation of Radiopharmaceuticals and Biotherapeutics at Health Canada since 2008. Her extensive experience in these roles spans over two decades, contributing to the development and assessment of health-related initiatives.
Education and Expertise
Agnes Klein is pursuing her MD at the University of Toronto, focusing on Endocrinology, Medical Biochemistry, and Public Health. She possesses specialized knowledge in pharmacogenomics, which examines how genetic variations influence individual responses to medications. Klein also has expertise in surrogate markers, which are critical in clinical trials as they serve as substitutes for direct measures of patient outcomes.
Background
Agnes Klein has a strong foundation in biomedical ethics, emphasizing the ethical considerations in medical and biological research. Prior to her current roles, she worked at Health Canada as the Chief of the Clinical Evaluation Division from 2000 to 2005. This position provided her with valuable experience in clinical evaluation processes and regulatory affairs.
Achievements
Throughout her career, Agnes Klein has contributed significantly to the field of health evaluation and policy development. Her work in pharmacogenomics and surrogate markers has implications for improving clinical trial methodologies and patient care. Klein's leadership at Health Canada has influenced the evaluation of radiopharmaceuticals and biotherapeutics, enhancing the understanding of their clinical effectiveness.